Allarity Therapeutics, Inc. entered into an exchange agreement on November 12, 2026, with Streeterville Capital, LLC, to restructure a promissory note. The company exchanged $3,000,000 of a promissory note (A-1 Note) issued on March 2, 2026, for 3,000 shares of Series B Preferred Stock. The Series B Preferred Stock has an initial stated value of $1,050 per share and an aggregate initial stated value of $3,150,000. The exchange was completed on November 16, 2026, following the effectiveness of the Certificate of Designation filed with the State of Delaware.
The Series B Preferred Stock accrues a preferred return of 9% per annum on its stated value, compounded daily, with quarterly payments due within five trading days after the end of each calendar quarter. The shares rank senior to the company’s Common Stock regarding dividends, distributions, and liquidation payments. The preferred stock carries no voting rights but includes protective provisions that require the consent of holders of a majority of the outstanding shares to amend the designation or authorize capital stock ranking senior to it. The designation also imposes covenants requiring the company to maintain its Exchange Act reporting status and a listing of its Common Stock on Nasdaq or NYSE American, while restricting additional debt or equity issuances and certain asset dispositions.
In addition to the capital restructuring, Allarity announced an expansion of its Phase 2 clinical trial for stenoparib in advanced ovarian cancer. The study, which is investigator-supported, is now open to patients with primary platinum-refractory disease and those whose disease is clinically evaluable but not measurable under standard criteria. The company reported that earlier observations from the trial included a median overall survival of 22 months in patients treated with stenoparib, which the company noted compares favorably to recent FDA-approved drugs showing a median overall survival of approximately 16 months in similar patients.